Squalamine lactate for the treatment of age-related macular degeneration

References

• Liu M, Regillo C. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical studies. Curr. Opin. Ophthalmol.15, 221–226 (2004).
   PubMedGoogle Scholar
• Chopar A, Chakravarthy U, Verma D. Clinical review: age related macular degeneration. Br. Med. J.326, 485–488 (2003).
   PubMed Web of Science ®Google Scholar
• Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol.48, 257–293 (2003).
   PubMed Web of Science ®Google Scholar
• Moore K, Wehrli S, Roder H et al. Squalamine: an aminosterol antibiotic from the shark. Proc. Natl Acad. Sci. USA90(4), 1354–1358 (1993).
   PubMed Web of Science ®Google Scholar
• Moriarty R, Enache L, Kinney W et al. Stereoselective synthesis of squalamine des-sulfate. Tetrehedron Letters36(29), 5139–5142 (1995).
   Web of Science ®Google Scholar
• Moriarty R, Tuladhar S, Guo L, Wehrli S. Synthesis of squalamine, a steroidal antibiotic from the shark. Tetrehedron Letters35(44), 8103–8106 (1994).
   Web of Science ®Google Scholar
• Pechulis A, Bellevue F III, Cioffi C et al. Synthesis of 24ξ-squalamine, an anti-infective steroidal polyamine. J. Org. Chem.60, 5121–5126 (1995).
   Web of Science ®Google Scholar
• Jones S, Kinney W, Zhang X, Jones L, Selinsky B. The synthesis and characterization of analogs of the antimicrobial compound squalamine: 6 beta-hydroxy-3-aminosterols synthesized from hyodeoxycholic acid. Steroids61(10), 565–571 (1996).
   PubMed Web of Science ®Google Scholar
• Moore K, Bevins C, Brasseur M et al. Antimicrobial peptides in the stomach of Xenopus laevis. J. Biol. Chem.266(29), 19851–19857 (1991).
   PubMed Web of Science ®Google Scholar
• Russo T, Mylotte D. Expression of the K54 and O4 specific antigen has opposite effects on the bactericidal activity of squalamine against an extraintestinal isolate of Escherichia coli. FEMS Microbiol. Lett.162(2), 311–315 (1998).
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Bernard E, Sadownik A, Regen S, Armstrong D. Antimicrobial activities of squalamine mimics. Antimicrob. Agents Chemother.41(7), 1433–1438 (1997).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev.18, 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9, 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Spilsbury K, Garrett K, Shen W, Constable I, Rakoczy P. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am. J. Pathol.157, 135–144 (2000).
   PubMed Web of Science ®Google Scholar
• Williams JI. Squalamine: a new angiostatic steroid. In: Anti-Angiogenic Agents in Cancer Therapy. Teicher BA (Ed.) Humana Press, Inc. NJ, USA, 153–174 (1999).
   Google Scholar
• Higgins R, Sanders R, Yan Y, Zasloff M, Williams J. Squalamine improves retinal neovascularization. Invest. Ophthalmol. Vis. Sci.41(6), 1507–1512 (2000).
   PubMed Web of Science ®Google Scholar
• Higgins RD, Yan Y, Geng Y, Zasloff M, Williams J. Regression of retinopathy by squalamine in a mouse model. Pediatr. Res.56(1), 144–149 (2004).
   PubMed Web of Science ®Google Scholar
• Ciulla T, Criswell M, Danis R, Williams J, McLane M, Holroyd K. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina23(6), 808–814 (2003).
   PubMed Web of Science ®Google Scholar
• Genaidy M, Kazi A, Peyman G et al. Effect of squalamine on iris neovascularization in monkeys. Retina22(6), 772–778 (2002).
   PubMed Web of Science ®Google Scholar
• Williams JI, Chen Q, Anderson GM, Kinney WA, Zasloff M. Structural elements of the steroid squalamine that contribute to it as a calmodulin chaperone and an angiostatic agent. Keystone Angiogenesis Meeting. CO, USA, 2000.
   Google Scholar
• Chen Q. The angiostatic sterol squalamine is a calmodulin chaperone. AACR-NCI-EORTC Meeting 1999.
   Google Scholar
• Chen Q. Identification of the intracellular target for squalamine as calmodulin. American Association for Cancer Research. CA, USA, Abstract 4120 (2000).
   Google Scholar
• Bhargava P, Marshall JL, Dahut W et al. A phase 1 and pharmacokinetic study of squalamine, a novel anti-angiogenic agent, in patients with advanced cancers. Clin. Cancer Res.7, 3912–3919 (2001).
   PubMed Web of Science ®Google Scholar
• Hao D, Hammond LA, Eckhardt SG et al. A phase 1 and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. Clin. Cancer Res.9, 2465–2471 (2003).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hammond LA, Carbone DP et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res.9, 4108–4115 (2003).
   PubMed Web of Science ®Google Scholar
• Connolly B, Desai A, Garcia CA, Thomas E, Gast MJ. Squalamine lactate (EVIZON™) for exudative age-related macular degeneration. Ophthalmol. Clin. N. Am.19, 381–391 (2006).
   PubMedGoogle Scholar
• Garcia CA, Quiroz-Mercado H, Uwaydat S et al. A phase I/II trial of squalamine lactate for the treatment of choridal neovascularization in age related macular degeneration (ARMD). Invest. Opthalmol. Vis. Sci.45, Abstract 2362 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia C, Connolly B, Thomas E et al. A phase 2 multi-dose pharmacokinetic study of EVIZON™ (squalamine lactate) for the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration (AMD). Association for Research in Vision and Ophthalmology (ARVO). FL, USA, Abstract 206 (2005).
   Google Scholar
• Ciulla TA, Rosberger DF, Katz RS et al. Safety and efficacy results from a phase 2, multicenter, randomized, controlled, masked study (MSI-1256F-208) of the effects of EVIZON™ (squalamine lactate for injection) with concommitant verteporfin in patients with wet AMD. 109th Meeting of the American Academy of Opthalmology. IL, USA (2005).
   Google Scholar
• Gast MJ, Regillo CD, Thomas EL, Garcia CA, Vogel R. Increased visual acuity in fellow affected eyes of subjects undergoing therapy with intravenous EVIZON™ (squalamine lactate) for exudative AMD. 24th Annual Meeting of the American Society of Retinal Specialists. Cannes, France (2006).
   Google Scholar